SpatialScore Ratio Predicts Immunotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting response to immunotherapy in cutaneous T cell lymphoma (CTCL) patients, such as pembrolizumab treatment, are inadequate, as existing biomarkers fail to accurately identify responders and non-responders, leading to suboptimal treatment outcomes.
Innovation Solution
A method involving a multiplexed binding assay on tumor tissue sections to measure the physical distances between effector immune cells and both cancer cells and immunosuppressive cells, calculating a SpatialScore ratio that predicts patient response to immunotherapy, allowing for stratification of patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing biomarkers (immunohistochemistry and gene expression profiling) are used to predict pembrolizumab response, then treatment can be initiated, but prediction accuracy is insufficient leading to inability to stratify responders and non-responders
Solution Approach 1:
The patent transitions from traditional 2D immunohistochemistry and bulk gene expression profiling to 3D spatial analysis of cellular neighborhoods. By measuring physical distances between effector immune cells, cancer cells, and immunosuppressive cells in three-dimensional tissue architecture, the method captures spatial relationships that previous 2D or bulk methods missed, achieving 80% prediction accuracy
Solution Approach 2:
The patent segments the tumor microenvironment into distinct cellular neighborhoods by identifying and measuring distances between specific cell types (effector immune cells, cancer cells, immunosuppressive cells). This segmentation approach allows independent analysis of spatial relationships between different cell populations, revealing that effector cells closer to cancer cells and farther from immunosuppressive cells predict response, a nuance lost in bulk analysis
2Productivity
If PD-1 blocking antibody pembrolizumab is administered to all patients, then treatment coverage is maximized, but rapid disease progression occurs in non-responders due to stimulated tumor cell growth
Solution Approach 1:
The patent performs spatial analysis of cellular neighborhoods before initiating pembrolizumab treatment to identify patients with effector immune cells positioned closer to cancer cells than to immunosuppressive cells. This preliminary stratification ensures that only patients with favorable spatial configurations (predicting 80% response rate) receive PD-1 blockade, preventing rapid progression in non-responders while maintaining high treatment coverage among selected patients
Solution Approach 2:
The patent introduces a spatial biomarker (distance ratio between effector immune cells to cancer cells versus immunosuppressive cells) as an intermediary selection criterion. This spatial metric acts as a mediator that bridges patient characteristics and treatment response, enabling rational patient selection that maximizes benefit while minimizing harm from inappropriate PD-1 blockade
Data Source
AI summary
Provided herein, among other things, is a method for predicting how a patient responds to immunotherapy. In some embodiments, the method may comprise: performing a multiplexed binding assay on a tissue section of a tumor obtained from a cancer patient to identify at least cancer cells, effector immune cells and immunosuppressive cells in the tissue section; measuring, for each cell of a plurality of the effector immune cells: (i) the physical distance to its most proximal cancer cell; and (ii) the physical distances to its most proximal immunosuppressive cell; and calculating, for each of the effector immune cells analyzed, the ratio of the distance measured in step (i) and distance measured in step (ii), wherein the ratio is predictive of the patient's response to immunotherapy. The method may be used to select patients for immunotherapy.